Developer docs
API playgroundTry for free, no card

Search company profiles

Proveo

Full company profile

uuid000v7sz

Namestring
Proveo
Websiteurl
proveoltda.com
Company typeenum
Private
Founded yearint
1997
Descriptiontext

Proveo (registered as Proveo Ltda) is a Colombian for-profit company headquartered in Bogotá, founded in 1997. According to the provided firmographic data, the company operates in the business, education, research, and analysis sector through the supply of laboratory equipment. With a headcount of 11-50 employees, Proveo fits the profile of a small-to-medium laboratory equipment distributor or supplier serving institutional, educational, or research customers in Colombia. The company's online presence is anchored at proveoltda.com, and the "Ltda" (Sociedad Limitada) corporate designation in both the URL and the legal structure confirms its Colombian limited liability status. The company is privately held, with no public ticker disclosed. No further detail on specific product lines, pricing, customer segments, distribution channels, partnerships, funding history, ownership structure, management team, or revenue mechanics is available in the provided sources.

The underlying business model — distribution or supply of laboratory equipment — implies transactions with research institutions, universities, hospitals, government laboratories, and possibly private clinical or industrial laboratories in Colombia. Pricing, contract structures, and go-to-market motions are not disclosed. No certifications, regulatory filings, geographic expansion footprint beyond Colombia, or subsidiary structure is documented.

Note on data integrity: the provided input also contains product and technology descriptions characterizing Proveo as a biotechnology firm developing antibody-drug conjugate (ADC) technologies, referencing a 2026 World ADC Conference appearance alongside peers Sygnature Discovery, Abzena, LOTTE Biologics, and Exelixis. This description conflicts with the firmographic identity of a 27-year-old Colombian laboratory equipment supplier and most likely reflects a data conflation with a separate, similarly-named biotech entity rather than the primary firmographic subject. Per the convention of preferring first-party registration data over third-party attributions for fundamental firmographic facts, the analysis below treats Proveo Ltda, the Bogotá laboratory equipment supplier, as the primary identity. This data conflict is the principal limitation on confidence across every analytical field below.

Short descriptiontext

Proveo (Proveo Ltda) is a private Colombian laboratory equipment supplier founded in 1997 and headquartered in Bogotá, serving the business, education, research, and analysis sectors with 11-50 employees.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBogotá, Colombia
HQ citystring
Bogotá
HQ countrystring
Colombia
HQ regionstring
Latin America
Markets served

Serves global market

Keyword5 values
antibody-drug conjugates, ADC technology development, biopharmaceutical research services, conjugation technologies, therapeutic payload development
Industry2 codes
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Biopharmaceutical R&D Services
Social media profiles1 record
Cost components4 values
Personnel, Technology or R&D, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Proveo develops and optimizes antibody-drug conjugate (ADC) technologies for biopharmaceutical clients, with a focus on payload diversity, site-specific conjugation methods, and scalable manufacturing strategies for next-generation ADC therapeutics. The company also supplies laboratory equipment to support research, education, and analysis activities.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Proveo is a biotechnology company specializing in antibody-drug conjugate (ADC) technology development. The company focuses on ADC innovations including payload diversity, site-specific conjugation methods, and manufacturing strategies, collaborating with other organizations in the ADC development ecosystem.

Product and service2 records
1ADC Technology Development
CategoryBiopharmaceutical R&D Services
Description

Development and optimization of antibody-drug conjugate (ADC) technologies, including payload diversity engineering, site-specific conjugation methods, and manufacturing strategies for next-generation ADC therapeutics, sold to pharmaceutical and biotech companies developing ADC-based drugs.

2Laboratory Equipment Supply
CategoryLaboratory Supplies
Description

Supply of laboratory equipment to support business, education, research, and analysis activities.

No data
Peers10 records
TypeDirect peer
Description

Specialist biologics CDMO/CRO with comprehensive ADC services spanning conjugation chemistry, payload-linker development, and GMP manufacturing. Directly comparable to Proveo's three core technology pillars.

TypeEmerging player
Description

Clinical-stage biotech developing innovative ADCs with proprietary payload and linker platforms. A focused emerging player in ADC technology development, comparable in scale and stage to Proveo.

TypeEmerging player
Description

Biotech developing ADCs and antibody-drug conjugates with novel payload and targeting approaches. A comparable emerging player in the ADC technology space.

TypeDirect peer
Description

Leading global ADC CRDMO offering end-to-end ADC development and manufacturing services. A direct competitor to Proveo in providing integrated ADC technology solutions to biopharma.

TypeDirect peer
Description

Korean biotech with proprietary ADC platform technology including site-specific conjugation and novel linker chemistry. A direct comparable in ADC platform development.

TypeBroad incumbent
Description

Large-scale biologics CDMO with growing ADC manufacturing capabilities. A much larger incumbent in the same ADC ecosystem where Proveo operates.

TypeDirect peer
Description

UK-based drug discovery CRO with a dedicated ADC discovery and development service line. Directly comparable to Proveo as an ADC technology and services provider serving biopharma clients.

TypeDirect peer
Description

German biotech developing proprietary ADC technology platforms, including novel payload chemistries and conjugation approaches. Comparable in technology focus to Proveo's payload diversity and site-specific conjugation efforts.

TypeBroad incumbent
Description

Global CDMO offering ADC development, conjugation, and manufacturing services as part of its broader biologics portfolio. Represents the broad incumbent end of the ADC services market.

TypeEmerging player
Description

German biotech developing next-generation ADCs with proprietary conjugation chemistries and stable linkers. An emerging player in the same technology domains Proveo targets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Proveo

Biopharmaceutical R&D Servicesproveoltda.com

Proveo (Proveo Ltda) is a private Colombian laboratory equipment supplier founded in 1997 and headquartered in Bogotá, serving the business, education, research, and analysis sectors with 11-50 employees.

What Proveo does

Proveo (registered as Proveo Ltda) is a Colombian for-profit company headquartered in Bogotá, founded in 1997. According to the provided firmographic data, the company operates in the business, education, research, and analysis sector through the supply of laboratory equipment. With a headcount of 11-50 employees, Proveo fits the profile of a small-to-medium laboratory equipment distributor or supplier serving institutional, educational, or research customers in Colombia. The company's online presence is anchored at proveoltda.com, and the "Ltda" (Sociedad Limitada) corporate designation in both the URL and the legal structure confirms its Colombian limited liability status. The company is privately held, with no public ticker disclosed. No further detail on specific product lines, pricing, customer segments, distribution channels, partnerships, funding history, ownership structure, management team, or revenue mechanics is available in the provided sources.

The underlying business model — distribution or supply of laboratory equipment — implies transactions with research institutions, universities, hospitals, government laboratories, and possibly private clinical or industrial laboratories in Colombia. Pricing, contract structures, and go-to-market motions are not disclosed. No certifications, regulatory filings, geographic expansion footprint beyond Colombia, or subsidiary structure is documented.

Note on data integrity: the provided input also contains product and technology descriptions characterizing Proveo as a biotechnology firm developing antibody-drug conjugate (ADC) technologies, referencing a 2026 World ADC Conference appearance alongside peers Sygnature Discovery, Abzena, LOTTE Biologics, and Exelixis. This description conflicts with the firmographic identity of a 27-year-old Colombian laboratory equipment supplier and most likely reflects a data conflation with a separate, similarly-named biotech entity rather than the primary firmographic subject. Per the convention of preferring first-party registration data over third-party attributions for fundamental firmographic facts, the analysis below treats Proveo Ltda, the Bogotá laboratory equipment supplier, as the primary identity. This data conflict is the principal limitation on confidence across every analytical field below.

Proveo firmographics

Firmographics
Name
Proveo
Website
https://proveoltda.com
Company type
Private
Founded year
1997
Operating status
Operating
Headcount range
11–50 employees
Short description
Proveo (Proveo Ltda) is a private Colombian laboratory equipment supplier founded in 1997 and headquartered in Bogotá, serving the business, education, research, and analysis sectors with 11-50 employees.
Ownership category
akta.pro rank

Proveo industry classification

Industry
Product category
Biopharmaceutical R&D Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Antibody-drug conjugates
  • ADC technology development
  • Biopharmaceutical research services
  • Conjugation technologies
  • Therapeutic payload development

Where Proveo is headquartered

Location

Headquarters

HQ city
Bogotá
HQ country
Colombia
HQ region
Latin America

Markets served

Proveo business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Supply Chain

Proveo product offering

Product offering

Core offering

Proveo develops and optimizes antibody-drug conjugate (ADC) technologies for biopharmaceutical clients, with a focus on payload diversity, site-specific conjugation methods, and scalable manufacturing strategies for next-generation ADC therapeutics. The company also supplies laboratory equipment to support research, education, and analysis activities.

Product overview

Proveo is a biotechnology company specializing in antibody-drug conjugate (ADC) technology development. The company focuses on ADC innovations including payload diversity, site-specific conjugation methods, and manufacturing strategies, collaborating with other organizations in the ADC development ecosystem.

Differentiator

Problem solved

Functional benefit

Products and services

  • ADC Technology Development Development and optimization of antibody-drug conjugate (ADC) technologies, including payload diversity engineering, site-specific conjugation methods, and manufacturing strategies for next-generation ADC therapeutics, sold to pharmaceutical and biotech companies developing ADC-based drugs.
  • Laboratory Equipment Supply Supply of laboratory equipment to support business, education, research, and analysis activities.

Companies that use Proveo

Customer profile

Segments1 record

Ideal customer profiles1 record

Proveo technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Proveo competitors and assessment

Company assessment

Direct peers

  • Abzena: Specialist biologics CDMO/CRO with comprehensive ADC services spanning conjugation chemistry, payload-linker development, and GMP manufacturing. Directly comparable to Proveo's three core technology pillars.
  • WuXi XDC: Leading global ADC CRDMO offering end-to-end ADC development and manufacturing services. A direct competitor to Proveo in providing integrated ADC technology solutions to biopharma.
  • LegoChem Biosciences: Korean biotech with proprietary ADC platform technology including site-specific conjugation and novel linker chemistry. A direct comparable in ADC platform development.
  • Sygnature Discovery: UK-based drug discovery CRO with a dedicated ADC discovery and development service line. Directly comparable to Proveo as an ADC technology and services provider serving biopharma clients.
  • Heidelberg Pharma: German biotech developing proprietary ADC technology platforms, including novel payload chemistries and conjugation approaches. Comparable in technology focus to Proveo's payload diversity and site-specific conjugation efforts.

Emerging players

  • Mersana Therapeutics: Clinical-stage biotech developing innovative ADCs with proprietary payload and linker platforms. A focused emerging player in ADC technology development, comparable in scale and stage to Proveo.
  • Pyxis Oncology: Biotech developing ADCs and antibody-drug conjugates with novel payload and targeting approaches. A comparable emerging player in the ADC technology space.
  • Tubulis: German biotech developing next-generation ADCs with proprietary conjugation chemistries and stable linkers. An emerging player in the same technology domains Proveo targets.

Broad incumbents

  • LOTTE Biologics: Large-scale biologics CDMO with growing ADC manufacturing capabilities. A much larger incumbent in the same ADC ecosystem where Proveo operates.
  • Lonza Group: Global CDMO offering ADC development, conjugation, and manufacturing services as part of its broader biologics portfolio. Represents the broad incumbent end of the ADC services market.

Market position

Strengths5 records

Weaknesses5 records

Key risks5 records

Key highlights5 records

Customer concentration

Proveo social profiles

Digital presence

Proveo financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Proveo leadership team

Management profile

Number of profiles

Proveo funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Proveo M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Proveo

What does Proveo do?

Proveo develops and optimizes antibody-drug conjugate (ADC) technologies for biopharmaceutical clients, with a focus on payload diversity, site-specific conjugation methods, and scalable manufacturing strategies for next-generation ADC therapeutics. The company also supplies laboratory equipment to support research, education, and analysis activities.

Is Proveo a public or private company?

Proveo is a private company. It is classified as unknown and is currently operating.

When was Proveo founded?

Proveo was founded in 1997. It employs 11 to 50 people.

Where is Proveo based?

Proveo is headquartered in Bogotá, Colombia, in the Latin America region.

Who are Proveo's main competitors?

Direct peers on record are Abzena, WuXi XDC, LegoChem Biosciences, Sygnature Discovery and Heidelberg Pharma. Emerging players are Mersana Therapeutics, Pyxis Oncology and Tubulis. Broad incumbents are LOTTE Biologics and Lonza Group.

Does Proveo have an API?

No public API is recorded for Proveo.

What industry is Proveo in?

Proveo's product category is Biopharmaceutical R&D Services. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales